Maring JG, Van Kuilenburg ABP, Haasjes J, Piersma H, Groen HJM, Uges DRA, Van Gennip AH, De Vries EGE (2002) Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 86(7):1028–1033. https://doi.org/10.1038/sj.bjc.6600208

Article  PubMed  PubMed Central  CAS  Google Scholar 

Etienne-Grimaldi M-C, Pallet N, Boige V, Ciccolini J, Chouchana L, Barin-Le Guellec C, Zaanan A, Narjoz C, Taieb J, Thomas F, Loriot M-A (2023) Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. Eur J Cancer 181:3–17. https://doi.org/10.1016/j.ejca.2022.11.028

Article  PubMed  CAS  Google Scholar 

Medicines and Healthcare Products Regulatory Agency (2020) 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity. Drug Saf Update 14:(3) https://www.gov.uk/drug-safety-update/5-fluorouracil-intravenous-capecitabine-tegafur-dpd-testing-recommended-before-initiation-to-identify-patients-at-increased-risk-of-severe-and-fatal-toxicity

Lau DK, Fong C, Arouri F, Cortez L, Katifi H, Gonzalez-Exposito R, Razzaq MB, Li S, Macklin-Doherty A, Hernandez MA, Hubank M, Fribbens C, Watkins D, Rao S, Chau I, Cunningham D, Starling N (2023) Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre. BMC Cancer 23(1):380. https://doi.org/10.1186/s12885-023-10857-8

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB (2014) DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). JNCI: Journal of the National Cancer Institute 106 (12)

Larrue R, Fellah S, Hennart B, Sabaouni N, Boukrout N, Van der Hauwaert C, Delage C, Cheok M, Perrais M, Cauffiez C (2024) Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity. Pharmacogenomics J 24(1):1

Article  PubMed  PubMed Central  CAS  Google Scholar 

Knikman JE, Zhai Q, Lunenburg CA, Henricks LM, Böhringer S, van der Lee M, de Man FM, Offer SM, Shrestha S, Creemers G-J (2024) Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in-and outside DPYD. Genome Med 16(1):101

Article  PubMed  PubMed Central  CAS  Google Scholar 

Diasio RB, Offer SM (2022) Testing for dihydropyrimidine dehydrogenase deficiency to individualize 5-fluorouracil therapy. Cancers (Basel) 14(13):3207

Article  PubMed  CAS  Google Scholar 

van den Wildenberg SA, Streng AS, van den Broek R, Broeren MA, Deenen MJ, van Dongen JL, Hanrath MA, Lapré C, Brunsveld L, Scharnhorst V (2022) Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions. J Pharm Biomed Anal 221:115027

Article  PubMed  Google Scholar 

Duley JA, Ni M, Shannon C, Norris RL, Sheffield L, Harris M, van Kuilenburg AB, Mead S, Cameron A, Helsby N (2016) Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. Eur J Pharm Sci 81:36–41

Article  PubMed  CAS  Google Scholar 

Duley JA, Ni M, Shannon C, Norris RL, Sheffield L, Cowley D, Harris M, van Kuilenburg AB, Helsby N, George R (2018) Preliminary evidence for enhanced thymine absorption: a putative new phenotype associated with fluoropyrimidine toxicity in cancer patients. Ther Drug Monit 40(4):495–502

Article  PubMed  CAS  Google Scholar 

Helsby NA, Duley J, Burns KE, Bonnet C, Jeong SH, Brenman E, Barlow P, Sharples K, Porter D, Findlay M (2020) A case–control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. Br J Clin Pharmacol 86(1):155–164

Article  PubMed  CAS  Google Scholar 

Burns KE, Chavani O, Jeong SH, Duley JA, Porter D, Findlay M, Strother RM, Helsby NA (2021) Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk. Cancer Chemother Pharmacol 87(5):711–716. https://doi.org/10.1007/s00280-021-04240-2

Article  PubMed  CAS  Google Scholar 

Burns KE, Allright D, Porter D, Findlay MP, Helsby NA (2019) A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells. Cancer Chemother Pharmacol 84(4):739–748. https://doi.org/10.1007/s00280-019-03904-4

Article  PubMed  CAS  Google Scholar 

Ghasemi A, Zahediasl S (2012) Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab 10(2):486–489. https://doi.org/10.5812/ijem.3505

Article  PubMed  PubMed Central  Google Scholar 

Douglas CE, Michael FA (1991) On distribution-free multiple comparisons in the one-way analysis of variance. Commun Statistics-Theory Methods 20(1):127–139

Article  Google Scholar 

R Core Team (2023) R: A Language and Environment for Statistical Computing. Vienna, Austria

StataCorp (2013) Stata Statistical Software: Release 13

Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL, London (2019) England) 394 (10197):521–532. doi:https://doi.org/10.1016/s0140-6736(19)31276-0

Article  CAS  Google Scholar 

Li M, Mindt S, Lück A, Hutzschenreuter U, Kollendt M, Lathan B, Zöller T, Frank-Gleich S, Lorentz C, Lamberti C, Sick C, Zingerle M, Tesch H, Stein W, Hebart H, Stosiek C, Sandner R, Fries S, Burkholder I, Hofheinz RD (2023) Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study. ESMO Open 8(2):101201. https://doi.org/10.1016/j.esmoop.2023.101201

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chamorey E, Francois E, Etienne M-C, Ferrero J-M, Peyrade F, Barranger E, Bozec A, Largillier R, Cassuto O, Viotti J (2020) DPD status and fluoropyrimidines-based treatment: high activity matters too. BMC Cancer 20:1–9

Article  Google Scholar 

De Mattia E, Polesel J, Scarabel L, Cecchin E (2024) Clinical implications of a gain-of-function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines. Front Pharmacol. https://doi.org/10.3389/fphar.2024.1516375

Article  PubMed  PubMed Central  Google Scholar 

Chionh F, Lau D, Yeung Y, Price T, Tebbutt N (2017) Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev CD008398. https://doi.org/10.1002/14651858.CD008398.pub2

Article  PubMed Central  Google Scholar 

Levy E, Piedbois P, Buyse M, Pignon J, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncology: Official J Am Soc Clin Oncol 16(11):3537–3541

Article  CAS  Google Scholar 

Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke S (2006) A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 94(7):964–968

Article  PubMed  PubMed Central  CAS  Google Scholar 

Stefanelli B, Sellitto C, De Bellis E, Torsiello M, Bertini N, Pezzullo AM, Corbi G, Sabbatino F, Pepe S, Tesse A, Conti V, Filippelli A (2022) Concomitant administration of capecitabine and folate supplements: need to encourage medication reconciliation. Pharmaceuticals (Basel Switzerland) 15(11). https://doi.org/10.3390/ph15111388

Chao C-J, Gardner I, Lin C-J, Yeh K-H, Lu W-C, Abduljalil K, Ho Y-F Administration mode matters for 5-fluorouracil therapy: physiologically based Pharmacokinetic evidence for avoidance of myelotoxicity by continuous infusion but not intravenous bolus. British Journal of Clinical Pharmacology n/a (n/a). https://doi.org/10.1111/bcp.16061

Hénin E, You B, VanCutsem E, Hoff P, Cassidy J, Twelves C, Zuideveld K, Sirzen F, Dartois C, Freyer G, Tod M, Girard P (2009) A dynamic model of Hand-and-Foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther 85(4):418–425. https://doi.org/10.1038/clpt.2008.220

Article  PubMed  CAS  Google Scholar 

Knikman JE, Lopez-Yurda M, Meulendijks D, Deenen MJ, Schellens JHM, Beijnen J, Cats A, Guchelaar H-J (2024) A nomogram to predict severe toxicity in DPYD Wild-Type patients treated with Capecitabine-Based anticancer regimens. Clin Pharmacol Ther 115(2):269–277. https://doi.org/10.1002/cpt.3100

Article  PubMed  CAS  Google Scholar 

Kovach JS, Beart RW (1989) Cellular pharmcology of fluorinated pyrimidines in vivo in man. Invest New Drugs 7:13–25

Article  PubMed  CAS  Google Scholar 

Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40(2):85–104. https://doi.org/10.2165/00003088-200140020-00002

Article  PubMed  CAS  Google Scholar 

McLeod H, Sludden J, Hardy S, Lock R, Hawksworth G, Cassidy J (1998) Autoregulation of 5-fluorouracil metabolism. Eur J Cancer 34(10):1623–1627

Article  PubMed  CAS